Omega Therapeutics Stock Performance
| OMGA Stock | USD 0.86 0.07 8.86% |
The company holds a Beta of 1.76, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Omega Therapeutics will likely underperform. At this point, Omega Therapeutics has a negative expected return of -0.62%. Please make sure to check Omega Therapeutics' total risk alpha, kurtosis, price action indicator, as well as the relationship between the value at risk and rate of daily change , to decide if Omega Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Omega Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Omega Therapeutics Stock Price Up 0.8 percent - MarketBeat | 09/10/2024 |
2 | Acquisition by Flagship Pioneering Inc. of 661764 shares of Omega Therapeutics at 17.0 subject to Rule 16b-3 | 09/12/2024 |
3 | Disposition of 87352 shares by Barbara Chan of Omega Therapeutics at 5.67 subject to Rule 16b-3 | 09/20/2024 |
4 | Disposition of 10000 shares by Young Richard A of Omega Therapeutics at 8.0 subject to Rule 16b-3 | 09/27/2024 |
5 | Insider Trading | 10/02/2024 |
6 | Acquisition by Young Richard A of 25000 shares of Omega Therapeutics at 2.2 subject to Rule 16b-3 | 10/31/2024 |
7 | Acquisition by Rosiello Robert L. of 50000 shares of Omega Therapeutics at 1.09 subject to Rule 16b-3 | 11/08/2024 |
8 | Armata Pharmaceuticals, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2024 |
9 | Acquisition by Kaan Certel of 340000 shares of Omega Therapeutics at 0.8284 subject to Rule 16b-3 | 11/15/2024 |
10 | Omega Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN | 11/22/2024 |
| Begin Period Cash Flow | 71 M |
Omega |
Omega Therapeutics Relative Risk vs. Return Landscape
If you would invest 145.00 in Omega Therapeutics on August 28, 2024 and sell it today you would lose (59.00) from holding Omega Therapeutics or give up 40.69% of portfolio value over 90 days. Omega Therapeutics is currently does not generate positive expected returns and assumes 6.6544% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Omega, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Omega Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Omega Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Omega Therapeutics, and traders can use it to determine the average amount a Omega Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0928
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OMGA |
Estimated Market Risk
| 6.65 actual daily | 59 59% of assets are less volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Omega Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Omega Therapeutics by adding Omega Therapeutics to a well-diversified portfolio.
Omega Therapeutics Fundamentals Growth
Omega Stock prices reflect investors' perceptions of the future prospects and financial health of Omega Therapeutics, and Omega Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Omega Stock performance.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (7.77) % | ||||
| Current Valuation | 141.27 M | ||||
| Shares Outstanding | 55.37 M | ||||
| Price To Book | 3.77 X | ||||
| Price To Sales | 6.89 X | ||||
| Revenue | 3.09 M | ||||
| Gross Profit | (74.02 M) | ||||
| EBITDA | (93.49 M) | ||||
| Net Income | (97.43 M) | ||||
| Cash And Equivalents | 173.66 M | ||||
| Cash Per Share | 3.63 X | ||||
| Total Debt | 128.43 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 13.46 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (91.51 M) | ||||
| Earnings Per Share | (1.32) X | ||||
| Market Capitalization | 43.52 M | ||||
| Total Asset | 204.37 M | ||||
| Retained Earnings | (334.63 M) | ||||
| Working Capital | 63.08 M | ||||
About Omega Therapeutics Performance
By analyzing Omega Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Omega Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Omega Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Omega Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.6 K | 2.7 K | |
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (1.68) | (1.60) |
Things to note about Omega Therapeutics performance evaluation
Checking the ongoing alerts about Omega Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Omega Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Omega Therapeutics generated a negative expected return over the last 90 days | |
| Omega Therapeutics has high historical volatility and very poor performance | |
| Omega Therapeutics has some characteristics of a very speculative penny stock | |
| Omega Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.09 M. Net Loss for the year was (97.43 M) with loss before overhead, payroll, taxes, and interest of (74.02 M). | |
| Omega Therapeutics currently holds about 173.66 M in cash with (91.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Omega Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Omega Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN |
- Analyzing Omega Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Omega Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Omega Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Omega Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Omega Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Omega Therapeutics' stock. These opinions can provide insight into Omega Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Omega Stock analysis
When running Omega Therapeutics' price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |